Novo Nordisk Investigational Site

Boca Raton, Florida 33486

0 studies enrolling now · 12 studies all time

What they study most

Delivery Systems, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hepatobiliary Disorders, Inflammation, Non-alcoholic Steatohepatitis, Rheumatoid Arthritis

Studies at this site

• A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes — Completed
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. — Completed
• Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes — Completed
• A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events — Completed
• Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes — Completed
• A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics — Stopped early
• Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes — Stopped early
• Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes — Stopped early
• Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes — Stopped early
• Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics — Completed
• Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily — Completed
• Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes — Completed